SARASOTA, Fla., Aug. 2, 2005 (PRIMEZONE) -- DNAPrint genomics, Inc. (OTCBB:DNAG) today announced that Dr. Matthew Thomas, Ph., D., one of the company's key forensic scientists, will make a presentation and participate in a workshop at a meeting of the International Association of Forensic Sciences (IAFS) August 21-25 in Hong Kong, China.
Dr. Thomas will speak on "The Role of Biogeographical Ancestry in the Modern Criminal Investigation" and will be assisted by Dr. Ripan Malhi of DNAPrint's Trace Genomics Division during a presentation with Beckman Coulter, a manufacturer of instrument systems for laboratories and the maker of the company's DNA processing equipment.
"DNAPrint genomics' DNAWITNESS(tm) forensics technology is utilized by Scotland Yard and other law enforcement agencies around the world," stated President and Chief Executive Officer Richard Gabriel. "The IAFS meeting will provide the company an excellent forum for making international forensics experts aware of the effectiveness of our technology and the contributions that it can make to solving crimes."
Founded in 1957, the Hong Kong-based IAFS is the only worldwide association that brings together academics and practicing professionals of various disciplines in forensic science. The association holds an international meeting every three years in a major world capital.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm), EURO-DNA(tm).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.